Collaboration, License and Other Strategic Agreements (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended			6 Months Ended		12 Months Ended
	Apr. 03, 2017	Feb. 28, 2017	Jul. 31, 2015	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2015
Collaborative Agreements
Net shares issued in connection with license agreement, value							$ 0	$ 12,555
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset				$ 0		$ 18,600	0	18,600
Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement	$ 50,000
Number of shares issued under arrangement (in shares)	600,000
Net shares issued in connection with license agreement, value	$ 13,500
Consideration recorded						83,500
IPR&D expense						5,800		5,800
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement		$ 60,000
Out-of-pocket expenses (up to)		$ 25,000
Velo Bio, LLC
Collaborative Agreements
Upfront payment, option agreement									$ 10,000
Velo Bio, LLC | Option Exercise and Regulatory Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)			$ 65,000
Velo Bio, LLC | Annual Sales Milestone Achievements
Collaborative Agreements
Future contingent payments (up to)			250,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum
Collaborative Agreements
Sales milestone targets			100,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum
Collaborative Agreements
Sales milestone targets			$ 900,000
Velo Bio, LLC | Royalty Threshold Achievement
Collaborative Agreements
Potential milestone payment, triggering event, royalty percentage			0.00%
Potential milestone payment, increased percentage			50.00%
Intrarosa | Endoceutics, Inc.
Collaborative Agreements
Out-of-pocket expenses (up to)					$ 20,000
Intrarosa | Endoceutics, Inc. | Developed technology rights
Collaborative Agreements
Finite-lived intangible assets						$ 77,700		$ 77,700
Intrarosa | Endoceutics, Inc. | Delivery Of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement					$ 10,000
Intrarosa | Endoceutics, Inc. | First Anniversary Of Closing
Collaborative Agreements
Payments related to collaborative arrangement				10,000
Intrarosa | Endoceutics, Inc. | Tiered Royalties
Collaborative Agreements
Potential milestone payment, triggering event, sales	$ 150,000						$ 150,000
Royalty percentage, maximum	20.00%						20.00%
Net sales threshold, future contingent payments	$ 1,000,000						$ 1,000,000
Period after first commercial sale	10 years						10 years
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales	$ 150,000						$ 150,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	15,000			15,000			15,000
Intrarosa | Endoceutics, Inc. | Second Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales	300,000						300,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	30,000			30,000			30,000
Intrarosa | Endoceutics, Inc. | Third Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales	500,000						500,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	$ 850,000			850,000			$ 850,000
Bremelanotide Products | Palatin Technologies, Inc. | Tiered Royalties
Collaborative Agreements
Period after first commercial sale							10 years
Bremelanotide Products | Palatin Technologies, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales							$ 250,000
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset				25,000			25,000
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application
Collaborative Agreements
Payments related to collaborative arrangement				20,000
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Collaborative Agreements
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset				60,000			60,000
Bremelanotide Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones over Course of License Agreement
Collaborative Agreements
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset				$ 300,000			$ 300,000